Clinical Trial Update: A Prospective, Randomized, Placebo-Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Administration of Lyophilized PRIM-DJ2727 or Placebo Given Orally in Subjects With Nonalcoholic Fatty Liver Disease [Phase 2]

View source ↗

Summary

A Phase 2 randomized, placebo-controlled pilot study evaluating the safety and fecal microbiome changes after oral lyophilized PRIM-DJ2727 in adults with nonalc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Fatty Liver Disease

Drugs mentioned

• PRIM-DJ2727

Snippet

Sponsor: The University of Texas Health Science Center, Houston | Conditions: Nonalcoholic Fatty Liver Disease (NAFLD) With History of Diabetes Melitus | Phase 2 | Status: WITHDRAWN